(Q34264270)

1 August 2017

1 reference

title

Progression, remission, regression of chronic renal diseases (English)

1 reference

1 August 2017

G Remuzzi

3

0 references

Piero Ruggenenti

series ordinal

1

object named as

P Ruggenenti

1 reference

1 August 2017

A Schieppati

2

1 reference

PubMed ID

11377666

1 August 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

1 August 2017

1 reference

1 August 2017

357

1 reference

1 August 2017

9268

1 reference

1 August 2017

1601-1608

1 reference

Structural and functional adaptation in renal failure.

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Report on management of renal failure in Europe, XXV, 1994 end stage renal disease and dialysis report. The EDTA-ERA Registry. European Dialysis and Transplant Association-European Renal Association

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Changing pattern of end-stage renal disease in central and eastern Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Pathophysiology of Progressive Nephropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Blood pressure and end-stage renal disease in men

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Premature cardiovascular disease in chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

LDL stimulates mesangial fibronectin production and chemoattractant expression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Impact of Arterial Blood Pressure and Albuminuria on the Progression of Diabetic Nephropathy in IDDM Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Effective Antihypertensive Treatment Postpones Renal Insufficiency in Diabetic Nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Pretreatment blood pressure reliably predicts progression of chronic nephropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Antiproteinuric effect of Losartan in patients with chronic renal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Cholesterol: a renal risk factor in diabetic nephropathy?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Lipids and the kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Effect of lipid reduction on the progression of renal disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Cigarette smoking and renal function impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Smoking and the kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Smoking as a risk factor for end-stage renal failure in men with primary renal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Remission Achieved in Chronic Nephropathy by a Multidrug Approach Targeted at Urinary Protein Excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Endothelin antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Vasopeptidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Vasopeptidase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Regulatory peptides and their antagonists in nephropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Glycosaminoglycans: a new paradigm in the prevention of proteinuria and progression of glomerular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

Progression and potential regression of glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

The role of diastolic blood pressure when treating isolated systolic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904728-0

7 January 2021

10.1016/S0140-6736(00)04728-0

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11377666